Compound A is produced from sevoflurane reacting with the CO2 absorbent. At concentrations above 50–150 ppm, Compound A is nephrotoxic in rodents. What is the current clinical significance of this finding for sevoflurane use in humans?
- A Sevoflurane is contraindicated in patients with renal failure due to proven nephrotoxicity
- B Sevoflurane must be used at >4 L/min fresh gas flow to prevent any Compound A formation
- C Compound A nephrotoxicity in rats has not been reproduced in humans at clinical concentrations; sevoflurane is considered safe with high fresh gas flows ✓
- D Compound A acts identically in humans and rats; maximum sevoflurane exposure is limited to 2 MAC-hours per procedure
Explanation
Compound A (fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether) is produced when sevoflurane reacts with the CO2 absorbent Sodalime/Baralyme, with formation increasing at low fresh gas flows, high temperatures, and dry absorbent. While it causes nephrotoxicity in rodents at high concentrations, multiple clinical studies in humans have shown NO evidence of renal toxicity at concentrations achieved in clinical anaesthesia. FDA labelling recommends fresh gas flows ≥2 L/min and limiting exposure to ≤2 MAC-hours at low flows, but most anaesthesiologists consider sevoflurane safe in renal patients at standard flows.
Reference: Morgan & Mikhail's Clinical Anesthesiology, 6th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.